JP2018502112A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018502112A5 JP2018502112A5 JP2017534822A JP2017534822A JP2018502112A5 JP 2018502112 A5 JP2018502112 A5 JP 2018502112A5 JP 2017534822 A JP2017534822 A JP 2017534822A JP 2017534822 A JP2017534822 A JP 2017534822A JP 2018502112 A5 JP2018502112 A5 JP 2018502112A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- subject
- therapeutic agent
- aav
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims description 17
- 229940124597 therapeutic agent Drugs 0.000 claims description 14
- 210000004556 brain Anatomy 0.000 claims description 11
- 108010035196 Mechanistic Target of Rapamycin Complex 1 Proteins 0.000 claims description 8
- 102000008135 Mechanistic Target of Rapamycin Complex 1 Human genes 0.000 claims description 8
- 239000013603 viral vector Substances 0.000 claims description 8
- 210000001577 neostriatum Anatomy 0.000 claims description 7
- 241000702423 Adeno-associated virus - 2 Species 0.000 claims description 6
- 102100027988 GTP-binding protein Rhes Human genes 0.000 claims description 6
- 101000578396 Homo sapiens GTP-binding protein Rhes Proteins 0.000 claims description 6
- 101150020518 RHEB gene Proteins 0.000 claims description 6
- 102000046951 Ras Homolog Enriched in Brain Human genes 0.000 claims description 6
- 108700019578 Ras Homolog Enriched in Brain Proteins 0.000 claims description 6
- 206010003694 Atrophy Diseases 0.000 claims description 4
- 241000702421 Dependoparvovirus Species 0.000 claims description 4
- 208000023105 Huntington disease Diseases 0.000 claims description 4
- 230000037444 atrophy Effects 0.000 claims description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 4
- 239000013598 vector Substances 0.000 claims description 4
- 230000002861 ventricular Effects 0.000 claims description 3
- 241001655883 Adeno-associated virus - 1 Species 0.000 claims description 2
- 241001634120 Adeno-associated virus - 5 Species 0.000 claims description 2
- 241000972680 Adeno-associated virus - 6 Species 0.000 claims description 2
- 230000002159 abnormal effect Effects 0.000 claims description 2
- 230000004900 autophagic degradation Effects 0.000 claims description 2
- 210000003169 central nervous system Anatomy 0.000 claims description 2
- 230000031154 cholesterol homeostasis Effects 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 229960003638 dopamine Drugs 0.000 claims description 2
- 230000002503 metabolic effect Effects 0.000 claims description 2
- 230000004065 mitochondrial dysfunction Effects 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 230000011664 signaling Effects 0.000 claims description 2
- 230000001771 impaired effect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462098085P | 2014-12-30 | 2014-12-30 | |
| US62/098,085 | 2014-12-30 | ||
| PCT/US2015/068034 WO2016109649A1 (en) | 2014-12-30 | 2015-12-30 | Methods and compositions for treating brain diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018502112A JP2018502112A (ja) | 2018-01-25 |
| JP2018502112A5 true JP2018502112A5 (enExample) | 2019-02-07 |
| JP6782701B2 JP6782701B2 (ja) | 2020-11-11 |
Family
ID=56285031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017534822A Active JP6782701B2 (ja) | 2014-12-30 | 2015-12-30 | 脳疾患を処置するための方法および組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11612641B2 (enExample) |
| EP (1) | EP3240577B1 (enExample) |
| JP (1) | JP6782701B2 (enExample) |
| KR (1) | KR102618947B1 (enExample) |
| CN (1) | CN107405414A (enExample) |
| AU (1) | AU2015374043B2 (enExample) |
| BR (1) | BR112017013674A2 (enExample) |
| CA (1) | CA2971687C (enExample) |
| ES (1) | ES2962439T3 (enExample) |
| SG (1) | SG11201704829QA (enExample) |
| WO (1) | WO2016109649A1 (enExample) |
| ZA (1) | ZA201704327B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2017006216A (es) | 2014-11-14 | 2018-08-29 | Voyager Therapeutics Inc | Composiciones y métodos para tratar la esclerosis lateral amiotrófica (ela). |
| KR102584655B1 (ko) | 2014-11-14 | 2023-10-06 | 보이저 테라퓨틱스, 인크. | 조절성 폴리뉴클레오티드 |
| EP3240577B1 (en) | 2014-12-30 | 2023-07-05 | University of Iowa Research Foundation | Therapeutic agent that activates mtorc1 function for use in treating huntington's disease |
| RU2758488C2 (ru) | 2016-05-18 | 2021-10-28 | Вояджер Терапьютикс, Инк. | Модулирующие полинуклеотиды |
| AU2017268382B2 (en) | 2016-05-18 | 2023-09-28 | Voyager Therapeutics, Inc. | Compositions and methods of treating Huntington's disease |
| CL2016003282A1 (es) * | 2016-12-21 | 2017-08-18 | Univ Chile | Virus aav/igf2, método de tratamiento genético y su uso en enfermedades relacionadas con mal plegamiento de proteínas tal como la enfermedad de huntington |
| WO2018132791A1 (en) * | 2017-01-16 | 2018-07-19 | The Regents Of The University Of California | Treatment of neurodegenerative conditions by disruption of rhes |
| WO2018204803A1 (en) | 2017-05-05 | 2018-11-08 | Voyager Therapeutics, Inc. | Compositions and methods of treating huntington's disease |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050255086A1 (en) | 2002-08-05 | 2005-11-17 | Davidson Beverly L | Nucleic acid silencing of Huntington's Disease gene |
| US20050009112A1 (en) | 2003-03-07 | 2005-01-13 | Fred Hutchinson Cancer Research Center, Office Of Technology Transfer | Methods for identifying Rheb effectors as lead compounds for drug development for diabetes and diseases associated with abnormal cell growth |
| KR20080018874A (ko) | 2005-04-27 | 2008-02-28 | 유니버시티 오브 플로리다 리서치 파운데이션, 아이엔씨. | 인간 질병과 관련된 돌연변이 단백질의 분해 촉진을 위한물질 및 방법 |
| KR101286870B1 (ko) * | 2009-11-30 | 2013-07-16 | (주)아모레퍼시픽 | 황기 추출물을 포함하는 대사 촉진 조성물 |
| WO2013061305A1 (en) * | 2011-10-28 | 2013-05-02 | Novartis Ag | Novel purine derivatives and their use in the treatment of disease |
| US9511036B2 (en) * | 2011-11-01 | 2016-12-06 | Children's Medical Center Corporation | Co-activation of mTOR and STAT3 pathways to promote neuronal survival and regeneration |
| HK1201828A1 (en) * | 2011-11-08 | 2015-09-11 | Intellikine, Llc | Treatment regimens using multiple pharmaceutical agents |
| US9095521B2 (en) * | 2012-02-02 | 2015-08-04 | Washington University | Methods for improving muscle strength |
| KR101626526B1 (ko) | 2014-10-30 | 2016-06-02 | 경북대학교 산학협력단 | ｈＲｈｅｂ를 유효성분으로 포함하는 허혈성 뇌질환의 예방 또는 치료용 조성물 |
| EP3240577B1 (en) | 2014-12-30 | 2023-07-05 | University of Iowa Research Foundation | Therapeutic agent that activates mtorc1 function for use in treating huntington's disease |
-
2015
- 2015-12-30 EP EP15876243.5A patent/EP3240577B1/en active Active
- 2015-12-30 SG SG11201704829QA patent/SG11201704829QA/en unknown
- 2015-12-30 AU AU2015374043A patent/AU2015374043B2/en active Active
- 2015-12-30 CN CN201580077153.9A patent/CN107405414A/zh active Pending
- 2015-12-30 JP JP2017534822A patent/JP6782701B2/ja active Active
- 2015-12-30 BR BR112017013674A patent/BR112017013674A2/pt not_active Application Discontinuation
- 2015-12-30 US US15/540,746 patent/US11612641B2/en active Active
- 2015-12-30 CA CA2971687A patent/CA2971687C/en active Active
- 2015-12-30 WO PCT/US2015/068034 patent/WO2016109649A1/en not_active Ceased
- 2015-12-30 KR KR1020177020915A patent/KR102618947B1/ko active Active
- 2015-12-30 ES ES15876243T patent/ES2962439T3/es active Active
-
2017
- 2017-06-26 ZA ZA2017/04327A patent/ZA201704327B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018502112A5 (enExample) | ||
| JP2020514286A5 (enExample) | ||
| JP2014512171A5 (enExample) | ||
| Nielsen et al. | Target temperature management after out-of-hospital cardiac arrest—a randomized, parallel-group, assessor-blinded clinical trial—rationale and design | |
| JP2021530548A (ja) | 遺伝子治療製剤を生産するための系および方法 | |
| JP2016538885A5 (enExample) | ||
| Huda et al. | Distinct transduction profiles in the CNS via three injection routes of AAV9 and the application to generation of a neurodegenerative mouse model | |
| JP2019513779A5 (enExample) | ||
| EP3880823A4 (en) | Therapeutic adeno-associated virus for treating pompe disease | |
| MY195439A (en) | Adeno-Associated Virus Vector Delivery of B-Sarcoglycan and Microrna-29 and the Treatment of Muscular Dystrophy | |
| JP2015520161A5 (enExample) | ||
| RU2021134920A (ru) | Композиции и способы деградации неправильно упакованных белков | |
| JP2019504003A5 (enExample) | ||
| JP2009526067A5 (enExample) | ||
| MX2021014338A (es) | Particulas virales modificadas y usos de estas. | |
| JP2016523956A5 (enExample) | ||
| JP2020537637A5 (enExample) | ||
| IL262852B1 (en) | Treatment of complement-mediated disorders | |
| Liu et al. | Environmental enrichment mitigates deficits after repetitive mild traumatic brain injury | |
| JP2017518316A5 (enExample) | ||
| JP2020503265A5 (enExample) | ||
| JP2020524689A5 (enExample) | ||
| Bhat et al. | Therapeutic approaches targeting aging and cellular senescence in Huntington's disease | |
| JP2018509154A5 (enExample) | ||
| EA202091194A1 (ru) | Вирусные векторы, содержащие области, кодирующие rdh12, и способы лечения дистрофий сетчатки |